A Campbell

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6620378/publications.pdf

Version: 2024-02-01

108 papers	2,599 citations	172386 29 h-index	206029 48 g-index
115 all docs	115 docs citations	115 times ranked	2992 citing authors

#	Article	IF	Citations
1	Elevated tricuspid regurgitant jet velocity in children and adolescents with sickle cell disease: association with hemolysis and hemoglobin oxygen desaturation. Haematologica, 2009, 94, 340-347.	1.7	164
2	Spontaneously increased production of nitric oxide and aberrant expression of the inducible nitric oxide synthase in vivo in the transforming growth factor beta 1 null mouse.. Journal of Experimental Medicine, 1996, 183, 2337-2342.	4.2	112
3	DESIGN OF THE SILENT CEREBRAL INFARCT TRANSFUSION (SIT) TRIAL. Pediatric Hematology and Oncology, 2010, 27, 69-89.	0.3	108
4	An embryonic/fetal beta-type globin gene repressor contains a nuclear receptor TR2/TR4 heterodimer. EMBO Journal, 2002, 21, 3434-3442.	3.5	100
5	Differences in the clinical and genotypic presentation of sickle cell disease around the world. Paediatric Respiratory Reviews, 2014, 15, 4-12.	1.2	97
6	Indications and Results of HLA-Identical Sibling Hematopoietic Cell Transplantation for Sickle Cell Disease. Biology of Blood and Marrow Transplantation, 2016, 22, 207-211.	2.0	97
7	Embryonic and fetal Î²-globin gene repression by the orphan nuclear receptors, TR2 and TR4. EMBO Journal, 2007, 26, 2295-2306.	3.5	89
8	Pulmonary Hypertension in Children and Adolescents with Sickle Cell Disease. Pediatric Cardiology, 2008, 29, 309-312.	0.6	89
9	Markers of Severe Vaso-Occlusive Painful Episode Frequency in Children and Adolescents with Sickle Cell Anemia. Journal of Pediatrics, 2012, 160, 286-290.	0.9	84
10	The LSD1 inhibitor RN-1 induces fetal hemoglobin synthesis and reduces disease pathology in sickle cell mice. Blood, 2015, 126, 386-396.	0.6	74
11	Meta-analysis of 2040 sickle cell anemia patients: BCL11A and HBS1L-MYB are the major modifiers of HbF in African Americans. Blood, 2012, 120, 1961-1962.	0.6	73
12	Elevated tricuspid regurgitation velocity and decline in exercise capacity over 22 months of follow up in children and adolescents with sickle cell anemia. Haematologica, 2011, 96, 33-40.	1.7	71
13	Treatment of Relapsed Wilmsâ€™ Tumor With High-Dose Therapy and Autologous Hematopoietic Stem-Cell Rescue: The Experience at Childrenâ€™s Memorial Hospital. Journal of Clinical Oncology, 2004, 22, 2885-2890.	0.8	64
14	Relationship of erythropoietin, fetal hemoglobin, and hydroxyurea treatment to tricuspid regurgitation velocity in children with sickle cell disease. Blood, 2009, 114, 4639-4644.	0.6	62
15	Angiogenic and Inflammatory Markers of Cardiopulmonary Changes in Children and Adolescents with Sickle Cell Disease. PLoS ONE, 2009, 4, e7956.	1.1	61
16	Prospective evaluation of haemoglobin oxygen saturation at rest and after exercise in paediatric sickle cell disease patients. British Journal of Haematology, 2009, 147, 352-359.	1.2	59
17	Prospective Echocardiography Assessment of Pulmonary Hypertension and Its Potential Etiologies in Children With Sickle Cell Diseaseâ€â€Conflicts of interest: Dr. Gordeuk has received grants from BioMarin Pharmaceutical Inc., Novato, California, and Actelion Pharmaceuticals Ltd., Allschwil, Switzerland, and is a consultant for Ikaria Holdings, Clinton, New Jersey.. American Journal of Cardiology, 2009, 104, 713-720.	0.7	56
18	Inpatient Health Care Use Among Adult Survivors of Chronic Childhood Illnesses in the United States. JAMA Pediatrics, 2006, 160, 1054.	3.6	55

#	Article	IF	Citations
19	An analysis of inpatient pediatric sickle cell disease: Incidence, costs, and outcomes. Pediatric Blood and Cancer, 2018, 65, e26758.	0.8	50
20	The TR2 and TR4 orphan nuclear receptors repress Gata1 transcription. Genes and Development, 2007, 21, 2832-2844.	2.7	49
21	Genetic determinants of haemolysis in sickle cell anaemia. British Journal of Haematology, 2013, 161, 270-278.	1.2	45
22	Abnormal Pulmonary Function and Associated Risk Factors in Children and Adolescents With Sickle Cell Anemia. Journal of Pediatric Hematology/Oncology, 2014, 36, 185-189.	0.3	44
23	Forced TR2/TR4 expression in sickle cell disease mice confers enhanced fetal hemoglobin synthesis and alleviated disease phenotypes. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 18808-18813.	3.3	42
24	Hematologic outcomes after total splenectomy and partial splenectomy for congenital hemolytic anemia. Journal of Pediatric Surgery, 2016, 51, 122-127.	0.8	39
25	<scp>mTOR</scp> Inhibition improves anaemia and reduces organ damage in a murine model of sickle cell disease. British Journal of Haematology, 2016, 174, 461-469.	1.2	36
26	Intestine-specific Disruption of Hypoxia-inducible Factor (HIF)-2Î± Improves Anemia in Sickle Cell Disease. Journal of Biological Chemistry, 2015, 290, 23523-23527.	1.6	35
27	Protective effect of HLA-DQB1 alleles against alloimmunization in patients with sickle cell disease. Human Immunology, 2016, 77, 35-40.	1.2	35
28	Impact of psychiatric diagnoses on hospital length of stay in children with sickle cell anemia. Pediatric Blood and Cancer, 2012, 58, 239-243.	0.8	33
29	Clinical outcomes of splenectomy in children: Report of the splenectomy in congenital hemolytic anemia registry. American Journal of Hematology, 2015, 90, 187-192.	2.0	33
30	Identifying Clinical and Research Priorities in Sickle Cell Lung Disease. An Official American Thoracic Society Workshop Report. Annals of the American Thoracic Society, 2019, 16, e17-e32.	1.5	33
31	Association of G6PD^{202A,376G} with lower haemoglobin concentration but not increased haemolysis in patients with sickle cell anaemia. British Journal of Haematology, 2010, 150, 218-225.	1.2	31
32	Clinical correlates of acute pulmonary events in children and adolescents with sickle cell disease. European Journal of Haematology, 2013, 91, 62-68.	1.1	30
33	PGC-1 Coactivator Activity Is Required for Murine Erythropoiesis. Molecular and Cellular Biology, 2014, 34, 1956-1965.	1.1	22
34	Oxidative Profile of Patients with Sickle Cell Disease. Medical Sciences (Basel, Switzerland), 2019, 7, 17.	1.3	22
35	Safety and efficacy of voxelotor in pediatric patients with sickle cell disease aged 4 to 11Âyears. Pediatric Blood and Cancer, 2022, 69, e29716.	0.8	21
36	Single-session Biofeedback-assisted Relaxation Training in Children With Sickle Cell Disease. Journal of Pediatric Hematology/Oncology, 2012, 34, 340-343.	0.3	20

#	Article	IF	Citations
37	Compound loss of function of nuclear receptors Tr2 and Tr4 leads to induction of murine embryonic Î²-type globin genes. Blood, 2015, 125, 1477-1487.	0.6	20
38	Safety of gadoliniumâ€based contrast material in sickle cell disease. Journal of Magnetic Resonance Imaging, 2011, 34, 917-920.	1.9	19
39	Paradoxical protection from atherosclerosis and thrombosis in a mouse model of sickle cell disease. British Journal of Haematology, 2013, 162, 120-129.	1.2	19
40	Tricuspid regurgitation velocity and other biomarkers of mortality in children, adolescents and young adults with sickle cell disease in the United States: The <scp>PUSH</scp> study. American Journal of Hematology, 2020, 95, 766-774.	2.0	19
41	Predictors of osteoclast activity in patients with sickle cell disease. Haematologica, 2011, 96, 1092-1098.	1.7	18
42	A study of the geographic distribution and associated risk factors of leg ulcers within an international cohort of sickle cell disease patients: the CASiRe group analysis. Annals of Hematology, 2020, 99, 2073-2079.	0.8	17
43	P-selectin glycoprotein ligand-1 inhibition blocks increased leukocyte-endothelial interactions associated with sickle cell disease in mice. Blood, 2012, 120, 3862-3864.	0.6	16
44	Low nitric oxide level is implicated in sickle cell disease and its complications in Ghana. Vascular Health and Risk Management, 2018, Volume 14, 199-204.	1.0	16
45	Attitudes of Ghanaian women toward genetic testing for sickle cell trait. International Journal of Gynecology and Obstetrics, 2011, 115, 264-268.	1.0	14
46	The Sickle Cell Disease Ontology: enabling universal sickle cell-based knowledge representation. Database: the Journal of Biological Databases and Curation, 2019, 2019, .	1.4	14
47	Red blood cell alloimmunization and minor red blood cell antigen phenotypes in transfused Ghanaian patients with sickle cell disease. Transfusion, 2019, 59, 2016-2022.	0.8	12
48	Association between eNOS Gene Polymorphism (T786C and VNTR) and Sickle Cell Disease Patients in Ghana. Diseases (Basel, Switzerland), 2018, 6, 90.	1.0	11
49	The Economic Burden of End-Organ Damage Among Medicaid Patients with Sickle Cell Disease in the United States: A Population-Based Longitudinal Claims Study. Journal of Managed Care & Specialty Pharmacy, 2020, 26, 1121-1129.	0.5	11
50	An Analysis of Racial and Ethnic Backgrounds Within the CASiRe International Cohort of Sickle Cell Disease Patients: Implications for Disease Phenotype and Clinical Research. Journal of Racial and Ethnic Health Disparities, 2021, 8, 99-106.	1.8	11
51	Sickle Cell Disease Proteinuria Is Not Associated With Systolic Blood Pressure, CSSCD-Defined Hypertension, or Family History Of Hypertension In An International Cohort Of SCD Patients. Blood, 2013, 122, 981-981.	0.6	11
52	A phase 1 doseâ€finding study of intravenous Lâ€citrulline in sickle cell disease: a potential novel therapy for sickle cell pain crisis. British Journal of Haematology, 2019, 184, 634-636.	1.2	10
53	Who Counsels Parents of Newborns Who Are Carriers of Sickle Cell Anemia or Cystic Fibrosis?. Journal of Genetic Counseling, 2013, 22, 218-225.	0.9	9
54	Increased stroke size following MCA occlusion in a mouse model of sickle cell disease. Blood, 2014, 123, 1965-1967.	0.6	9

#	Article	IF	Citations
55	Correlation Between Soluble Endothelial Adhesion Molecules and Nitric Oxide Metabolites in Sickle Cell Disease. Medical Sciences (Basel, Switzerland), 2019, 7, 1.	1.3	9
56	Linear Distance from the Locus Control Region Determines Îµ-Globin Transcriptional Activity. Molecular and Cellular Biology, 2007, 27, 5664-5672.	1.1	8
57	Coming of Age With Sickle Cell Disease and the Role of Patient as Teacher. Journal of the National Medical Association, 2010, 102, 1073-1078.	0.6	8
58	The CYB5R3 c . 350C >G and G6PD A alleles modify severity of anemia in malaria and sickle cell disease. American Journal of Hematology, 2020, 95, 1269-1279.	2.0	8
59	Correlation of lipid peroxidation and nitric oxide metabolites, trace elements, and antioxidant enzymes in patients with sickle cell disease. Journal of Clinical Laboratory Analysis, 2020, 34, e23294.	0.9	8
60	Age of first pain crisis and associated complications in the CASiRe international sickle cell disease cohort. Blood Cells, Molecules, and Diseases, 2021, 88, 102531.	0.6	8
61	All of the human Î²â€type globin genes compete for LCR enhancer activity in embryonic erythroid cells of yeast artificial chromosome transgenic mice. FASEB Journal, 2009, 23, 4335-4343.	0.2	7
62	Levels of Soluble Endothelium Adhesion Molecules and Complications among Sickle Cell Disease Patients in Ghana. Diseases (Basel, Switzerland), 2018, 6, 29.	1.0	7
63	Will the changing therapeutic landscape meet the needs of patients with sickle cell disease?. Lancet Haematology,the, 2021, 8, e306-e307.	2.2	7
64	Estimated SARS-CoV-2 Seroprevalence in Healthy Children and Those with Chronic Illnesses in the Washington Metropolitan Area as of October 2020. Pediatric Infectious Disease Journal, 2021, 40, e272-e274.	1.1	7
65	Low Rates of Cerebral Infarction after Hematopoietic Stem Cell Transplantation in Patients with Sickle Cell Disease at High Risk for Stroke. Transplantation and Cellular Therapy, 2021, 27, 1018.e1-1018.e9.	0.6	7
66	Screening for new red blood cell alloantibodies after transfusion in patients with sickle cell disease. Transfusion, 2021, 61, 2255-2264.	0.8	6
67	Global geographic differences in healthcare utilization for sickle cell disease pain crises in the CASiRe cohort. Blood Cells, Molecules, and Diseases, 2021, 92, 102612.	0.6	6
68	Hereditary Persistence of Fetal Hemoglobin Caused by Single Nucleotide Promoter Mutations in Sickle Cell Trait and Hb SC Disease. Hemoglobin, 2016, 40, 64-65.	0.4	5
69	Elevated Proangiogenic Markers are Associated with Vascular Complications within Ghanaian Sickle Cell Disease Patients. Medical Sciences (Basel, Switzerland), 2018, 6, 53.	1.3	5
70	Serum Iron Levels and Copper-to-Zinc Ratio in Sickle Cell Disease. Medicina (Lithuania), 2019, 55, 180.	0.8	5
71	Annual Academy of Sickle Cell and Thalassaemia (ASCAT) conference: a summary of the proceedings. BMC Proceedings, 2020, 14, 21.	1.8	5
72	Longâ€term hematologic and clinical outcomes of splenectomy in children with hereditary spherocytosis and sickle cell disease. Pediatric Blood and Cancer, 2020, 67, e28290.	0.8	5

#	Article	IF	Citations
73	Parvovirus B19 infection in sickle cell disease: An analysis from the Centers for Disease Control haemoglobinopathy blood surveillance project. Transfusion Medicine, 2020, 30, 226-230.	0.5	5
74	Sickle Cell Vision: A PatientÊ¼s Photographic Illustration of Coping. Academic Medicine, 2010, 85, 1210.	0.8	4
75	Melanoma tumor growth is accelerated in a mouse model of sickle cell disease. Experimental Hematology and Oncology, 2015, 4, 19.	2.0	4
76	The genetic basis of asymptomatic codon 8 frameâ€shift (<scp>HBB</scp>:c25_26del<scp>AA</scp>) Î²⁰â€thalassaemia homozygotes. British Journal of Haematology, 2016, 172, 958-965.	1.2	4
77	TR2/TR4 overexpression in a humanized sickle cell disease mouse model decreases RBC adhesion to VCAM-1. Blood Cells, Molecules, and Diseases, 2015, 55, 316-317.	0.6	3
78	Disseminated Intravascular Coagulation and Acute Liver Injury from Ethanol Embolization of an Arteriovenous Malformation. Journal of Vascular and Interventional Radiology, 2018, 29, 437-439.	0.2	3
79	Diagnosis patterns of sickle cell disease in Ghana: a secondary analysis. BMC Public Health, 2021, 21, 1719.	1.2	3
80	Plasma Level of NT-Pro-BNP In Children with Sickle Cell Disease Is Associated with Degree of Anemia and Left Ventricular Measures: The PUSH Study. Blood, 2010, 116, 948-948.	0.6	2
81	Pulmonary Function Tests and Their Correlation with Tricuspid Regurgitant Jet Velocity in Pediatric Sickle Cell Disease Patients.. Blood, 2007, 110, 2262-2262.	0.6	2
82	Prospective Evaluation of the Prevalence of Elevated Tricuspid Regurgitant Jet Velocity and Associated Clinical and Echocardiographic Factors in Children and Adolescents with Sickle Cell Disease.. Blood, 2007, 110, 3388-3388.	0.6	2
83	A Crash Course in Sickle Cell Disease. MedEdPORTAL: the Journal of Teaching and Learning Resources, 0, , .	0.5	2
84	Hemonectin: a novel hematopoietic adhesion molecule. Progress in Clinical and Biological Research, 1990, 352, 97-105.	0.2	2
85	Parentsâ€™ Experiences and Needs Regarding Infant Sickle Cell Trait Results. Pediatrics, 2022, 149, .	1.0	2
86	Influence of single parenthood on cardiopulmonary function in pediatric patients with sickle cell anemia. Blood Advances, 2020, 4, 3311-3314.	2.5	1
87	Analysis of Fetal Hemoglobin Expression within Humanized Sickle Cell Disease Mice Overexpressing the TR2/4 Transgene.. Blood, 2010, 116, 1619-1619.	0.6	1
88	Predictors of Mortality in Children and Adolescents with Sickle Cell Disease: The PUSH Study. Blood, 2011, 118, 515-515.	0.6	1
89	Epidemiology and Risk Factors for Pain In Children and Adolescent with Sickle Cell Anemia.. Blood, 2010, 116, 1651-1651.	0.6	1
90	Pediatric Sickle Cell Disease and the COVID-19 Pandemic: A Year in Review at Children's National Hospital. Blood, 2021, 138, 3036-3036.	0.6	1

#	Article	IF	Citations
91	Frequency of Vaso-Occlusive Crises Is Associated with Health-Related Quality of Life in Pediatric Patients with Sickle Cell Disease: US Cross-Sectional Surveys of Adolescents and Caregivers. Blood, 2021, 138, 490-490.	0.6	1
92	Association of Hemolysis with Clinical Manifestations of Sickle Cell Disease. Blood, 2008, 112, 2482-2482.	0.6	0
93	Lower Ferritin Concentrations in Children with Sickle Cell Disease Are Associated with Decreased Hemolysis and Lower Tricuspid Regurgitant Velocity. Blood, 2008, 112, 4810-4810.	0.6	0
94	Oxygen Desaturation at Rest and after Exercise in Pediatric Sickle Cell Disease Patients: Correlations with Hemolysis and Elevated Tricuspid Regurgitant Jet Velocity.. Blood, 2008, 112, 1423-1423.	0.6	0
95	Lower Ferritin Concentrations Are Associated with Decreased Hemolysis in Sickle Cell Disease Children without Iron Overload.. Blood, 2009, 114, 2571-2571.	0.6	0
96	Hemolysis-Associated Elevation in Tricuspid Regurgitation Velocity Predicts Reduction in Six-Minute Walk Distance After Two Years of Follow up in Children and Adolescents with Sickle Cell Disease.. Blood, 2009, 114, 574-574.	0.6	0
97	Evaluation of Exercise Capacity In Children with SCD by Six Minute Walk Test. Blood, 2010, 116, 2664-2664.	0.6	0
98	Serum B12 Levels In Children with Sickle Cell Disease Are Lower Than In Healthy Control Subjects. Blood, 2010, 116, 1647-1647.	0.6	0
99	Severe Impairment of Î³-Globin Gene Silencing in an Asymptomatic Adult Patient Homozygous for the Codon 8 (â€“AA) Frame-Shift Î²0-Thalassemia Mutation. Blood, 2012, 120, 1022-1022.	0.6	0
100	Prediction of Fetal Hemoglobin in Sickle Cell Anemia Using a Genetic Risk Score. Blood, 2012, 120, 3216-3216.	0.6	0
101	Genetic Determinants of Hemolysis in Sickle Cell Anemia.. Blood, 2012, 120, 2104-2104.	0.6	0
102	Improved Anemia, Organomegaly and Sustained Fetal Hemoglobin Induction within Aging TR2/TR4 Overexpressing UAB Sickle Cell Mice. Blood, 2012, 120, 3248-3248.	0.6	0
103	Patients Homozygous For Codon 8 (â€“AA) Frame-Shift Î²0-Thalassemia Mutation With Markedly Increased HbF. Blood, 2013, 122, 3455-3455.	0.6	0
104	Cardiopulmonary Functional Status in Children with SCD at Baseline: Pulse Pressure As a Biomarker of Early Compromise. Blood, 2014, 124, 2663-2663.	0.6	0
105	Hydroxyurea Shows Clinical Benefit without Alteration of Fetal Hemoglobin, MCV, or Hemoglobin in Unselected Adult and Pediatric Patients with Sickle Cell Anemia. Blood, 2015, 126, 2187-2187.	0.6	0
106	History of Asthma is Associated with Albuminuria within an International Pediatric Cohort of Sickle Cell Disease Patients: A Casire Group Analysis. Blood, 2016, 128, 3668-3668.	0.6	0
107	An Analysis of Racial and Ethnic Backgrounds within the Casire International Cohort of Sickle Cell Disease Patients: Implications for Disease Phenotype and Clinical Research. Blood, 2019, 134, 2305-2305.	0.6	0
108	OUP accepted manuscript. Pain Medicine, 2022, , .	0.9	0